The Effectiveness of the Modified Bundle in the Prevention of VAP.

Sponsor
Andrzej Frycz Modrzewski Krakow University (Other)
Overall Status
Completed
CT.gov ID
NCT04038814
Collaborator
(none)
386
1
13.4
28.7

Study Details

Study Description

Brief Summary

Ventilator-associated pneumonia (VAP) is an important cause of prolonged intensive care unit and hospital length of stay, healthcare costs and mortality in mechanically ventilated patients. There are an international guidelines for VAP diagnosis, treatment and prevention (Infectious Diseases Society of America(IDSA)/American Thoracic Society (ATS) 2016 and European Respiratory Society (ERS) / European Society of Intensive Care Medicine (ESICM) / European Society of Clinical Microbiology and Infectiuos Diseases (ESCMID) / Asociacion Latinoamericana del Torax (ALAT) 2017) routinely used in most ICUs. The investigator planed on comparing two strategies for prevention of VAP in mechanically ventilated patients: the routine VAP bundle ( historical group - VAP1) and the modified VAP bundle ( study group - VAP2) by using 3 modifications ( Shiley Evac Endotracheal tube with TaperGuard Cuff, Automatic continuous subglottic secretion drainage (SSD) and continuous tube cuff pressure monitoring).

The aim of the study is an assessment of the effectiveness of the modified prevention of VAP in reduction of: early and late VAP cases, mechanical ventilation days (MV), length of stay (LOS) in the ICU, 28 day mortality and multi drug resistent pathogens (MDR) cases in adult ICU patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Routine prevention of VAP
  • Procedure: Modified prevention of VAP

Study Design

Study Type:
Observational
Actual Enrollment :
386 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
The Effectiveness of the Modified Bundle in the Prevention of Ventilator-associated Pneumonia in Adult Patients in the Intensive Care Unit.
Actual Study Start Date :
Jun 1, 2018
Actual Primary Completion Date :
Jul 1, 2019
Actual Study Completion Date :
Jul 15, 2019

Arms and Interventions

Arm Intervention/Treatment
VAP1 - historical group

Routine prevention of VAP

Procedure: Routine prevention of VAP
Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) < 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax

VAP2 - study group

Modified prevention of VAP

Procedure: Modified prevention of VAP
3 modifications of the routine bundle in the prevention of VAP: Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes, Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg), Automatic continuous subglottic secretion drainage

Outcome Measures

Primary Outcome Measures

  1. Early VAP [day: 2 - 5 of mechanical ventilation]

    Total VAP cases in the ICU ( CEPPIS /Chest Echocardiography and Procalcitonin Pulmonary Infection Score/ criteria ) with early beginning of the pneumonia symptoms.

  2. Late VAP [day: 6 - the last day in ICU]

    total VAP cases in the ICU ( CEPPIS criteria ) with late beginning of the pneumonia symptoms

Secondary Outcome Measures

  1. LOS [day: 1 - the last day in the ICU, but at least 2 days]

    lenght of stay in the ICU (days)

  2. MV [day: 1 - the last day in the ICU, but at least 2 days]

    Duration of mechanical ventilation (days) in the ICU

  3. nonMV [day: 1 - the last day in the ICU,]

    Total non mechanical ventilation days in the ICU

  4. Mortality [day: 1 - 28]

    Mortality of adult mechanically ventilated patients in the ICU

  5. MDR [day: 1 - the last day in the ICU,]

    Number of cases with multi drug resistant (MDR) pathogens detected in specimens of mucus taken from the lower airways in mechanically ventilated patients in the ICU.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

VAP2 - study group

  • mechanically ventilated patients with an artificial airways (endotracheal tube, tracheostomy tube)

  • age over 18 years

  • modified bundle in the prevention of VAP

VAP1 - historical group

  • mechanically ventilated patients with an artificial airways (endotracheal tube, tracheostomy tube)

  • patients hospitalised in the ICU for last 12 months before modified bundle in the prevention of VAP has been started (from 01.05.2017 to 30.04.2018)

  • age over 18 years

  • routine bundle in the prevention of VAP

Exclusion Criteria:
  • lack of an informed consent in awake patients in the ICU

  • age under 18 years

  • patients with no mechanical ventilation in the ICU

  • patients with probability of mechanical ventilation days and LOS in the ICU less than 48 hours

  • patients intubated and mechanically ventilated without the bundle in the prevention of VAP for a period of time longer than 12 hours before the admission to the ICU

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anaesthesiology and Intensive Care Unit St. Raphael Hospital Kraków Małopolska Poland 30-693

Sponsors and Collaborators

  • Andrzej Frycz Modrzewski Krakow University

Investigators

  • Principal Investigator: JAROSLAW PAWLIK, MD, Andrzej Frycz Modrzewski Krakow University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
JAROSLAW PAWLIK, MD, Specialist of anaesthesiology and intensive care, An assistant of The Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University
ClinicalTrials.gov Identifier:
NCT04038814
Other Study ID Numbers:
  • AFMKrakowU
First Posted:
Jul 31, 2019
Last Update Posted:
Jul 31, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by JAROSLAW PAWLIK, MD, Specialist of anaesthesiology and intensive care, An assistant of The Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 31, 2019